MedTrace Logo

Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)

NCT06472934 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 498

Last updated 2025-11-28

No results posted yet for this study

Summary

This is a multi-centric, open-label, randomized trial to evaluate the safety and efficacy of temporary discontinuation of beta-blocker treatment in patients undergoing transcatheter aortic valve replacement.

Conditions

  • Aortic Stenosis

Interventions

OTHER

Transcatheter aortic valve replacement in the absence of B-blocker treatment

Transcatheter aortic valve replacement (TAVR) is performed in patients that temporarily pause B-blocker treatment.

OTHER

Transcatheter aortic valve replacement

Transcatheter aortic valve replacement (TAVR) is performed in patients that do not temporarily pause B-blocker treatment.

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Thomas Nestelberger, PD Dr. · University Hospital Basel, Department of Cardiology & Cardiovascular Research Institute Basel (CRIB)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-04
Primary Completion
2028-05-31
Completion
2028-05-31

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06472934 on ClinicalTrials.gov